Questions About Cancer? 1-800-4-CANCER

Childhood Rhabdomyosarcoma Treatment (PDQ®)

Health Professional Version
Last Modified: 10/29/2014

Changes to This Summary (10/29/2014)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information

Added Dumont et al. as reference 43.

Cellular Classification

Added text about an algorithm that may predict fusion status in alveolar rhabdomyosarcoma by using four immunohistochemical markers (cited Rudzinski et al. as reference 16).

Added text about the spindle cell/sclerosing histology of rhabdomyosarcoma, including information about the NCOA2 gene rearrangements and the MYOD1 mutation (cited Nascimento et al., Mosquera et al., Kohsaka et al., Agaram et al., and Szuhai et al. as references 26, 27, 28, 29, and 30, respectively).

Previously Untreated Childhood Rhabdomyosarcoma

Added Casey et al. as reference 76.

Added text to state that in a report from the German Cooperative Weichteilsarkom Studien trials, 32 patients had an event-free survival and overall survival of 47% at 5 years; in addition, patients with embryonal histology fared significantly better than did patients with alveolar histology (cited Fuchs et al. as reference 78 and level of evidence 3iiiA).

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.